Loading organizations...
Noetik is an AI-native biotechnology company focused on discovering and developing novel cancer immunotherapies. It employs advanced machine learning, leveraging human multimodal spatial omics data to build sophisticated foundation models. This approach enables Noetik to identify and develop precision immune oncology assets, addressing complex challenges in cancer treatment.
Ron Alfa, MD, PhD, and Jacob Rinaldi co-founded Noetik around 2021, from the insight that AI could solve drug problems beyond human capabilities. Dr. Alfa, a physician-scientist, and Rinaldi held leadership roles at Recursion and the Parker Institute for Cancer Immunotherapy, informing their AI-first oncology vision.
Noetik's platform aims to accelerate the development of more effective cancer therapies. Focusing on critical cancer types, the company seeks to fundamentally reshape how new treatments are identified. Its long-term vision involves leveraging AI models and proprietary datasets to deliver new generation immunotherapies, profoundly impacting future cancer care.
Noetik has raised $54.0M across 2 funding rounds.
Noetik has raised $54.0M in total across 2 funding rounds.
Noetik has raised $54.0M across 2 funding rounds. Most recently, it raised $40.0M Series A in August 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 1, 2024 | $40M Series A | Polaris Partners | Arkitekt Ventures, AV8 Ventures, James Hardiman, Dcvc (data Collective), Foundation Capital, OrbiMed, Polaris Partners, Zetta Venture Partners, Chris Gibson, Jack Boren, MEI Z. | Announced |
| Sep 1, 2023 | $14M Seed | Dcvc (data Collective) | Arkitekt Ventures, AV8 Ventures, Builders VC, James Hardiman, Dimension Capital, Foundation Capital, FPV Fund, Hummingbird Ventures, Kinnevik, OrbiMed, Polaris Partners, True Ventures, Zetta Venture Partners, Chris Gibson, Henry Kravis, Jack Boren, MEI Z., Rajiv Chegu | Announced |
Noetik has raised $54.0M in total across 2 funding rounds.
Noetik's investors include Polaris Partners, Arkitekt Ventures, AV8 Ventures, James Hardiman, DCVC (Data Collective), Foundation Capital, OrbiMed, Zetta Venture Partners, Chris Gibson, Jack Boren, Mei Z., Builders VC.
Noetik is an AI-native biotechnology company founded in 2022, headquartered in South San Francisco, CA, that develops precision cancer therapies using machine learning models trained on multimodal human patient data.[1][2][3][5] Its proprietary platforms, including OCTO and Perturb-map, create virtual cell models from massive datasets—over 1,000 tumor samples and 200 million cells—to identify therapeutic targets, enable biomarker selection, patient stratification, and bridge the gap between drug discovery and clinical success.[1][2][4] Noetik serves oncology patients and drug developers by tackling the translational gap in cancer treatment, with early traction from a proprietary lung cancer dataset and backing from top investors like Polaris Partners, DCVC, Khosla Ventures, and others; growth momentum includes scalable AWS infrastructure for AI workloads and expansion to 256 NVIDIA H100 GPUs.[1][4]
Noetik was founded in 2022 by biotech and AI veterans addressing the "translation gap" between basic drug discovery and clinical success in cancer therapies, fueled by the convergence of computational biology and large-scale data.[1][3] Key co-founders include Ron Alfa, MD, PhD (CEO), a physician-scientist and former Senior Vice President and acting CSO at Recursion Pharmaceuticals; Jacob Rinaldi, PhD (CSO), ex-Head of Oncology at Recursion with Genentech experience in deep learning for cancer vaccines and target discovery (Stanford Neuroscience PhD); and Lacey Padron, PhD (CTO), who oversees multimodal data processing.[2][4] The idea emerged from their work at Recursion and the Parker Institute for Cancer Immunotherapy, where they built significant proprietary datasets, including one of the largest multimodal lung cancer collections, demonstrating target discovery via self-supervised learning—pivotal early traction that propelled Noetik forward.[2]
Noetik stands out in AI-biotech through:
Noetik rides the AI-biotech convergence wave, particularly in precision oncology, where machine learning deciphers tumor complexity beyond human capability amid rising multimodal data from clinical cohorts.[1][3][4] Timing is ideal post-2022 AI boom, with foundation models enabling self-supervised learning on hard-to-replicate human datasets, countering high cancer drug failure rates (often >90% in trials).[2][3] Market forces like scalable cloud compute (AWS/NVIDIA) and investor interest in AI-driven drug discovery favor Noetik, influencing the ecosystem by pioneering "AI-native" biotech—setting standards for data integration, virtual modeling, and immunotherapy that could reshape clinical translation and patient outcomes.[1][4]
Noetik is poised to lead next-gen precision cancer therapies, with next steps including model scaling, immunotherapy pipeline advancement, and potential clinical trials leveraging its unique human-data edge.[1][2][4] Trends like multimodal foundation models, spatial omics, and compute democratization will amplify its momentum, potentially evolving its influence from target discovery to full-stack drug development partnerships. As an early mover in AI-oncology, Noetik exemplifies how bridging human biology and machine intelligence transforms unmet needs into breakthroughs—watch for pivotal data readouts that could redefine clinical success.
